Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eon Labs famotidine

This article was originally published in The Tan Sheet

Executive Summary

Firm's application (ANDA 76-101) for generic equivalent to J&J/Merck's Pepcid AC approved by FDA Oct. 21. Eon likely will partner with another company to bring the H2 antagonist to market but has no imminent launch plans. Five other companies hold ANDA approval for 10 mg tablets (1"The Tan Sheet" April 8, 2002, In Brief)...

You may also be interested in...

Torpharm ANDA

Private labeler's famotidine 10 mg tablets (J&J/Merck's Pepcid AC) approved by FDA March 12. ANDA (75-610) marks fifth private label approval for the H2 antagonist, behind Ivax, Teva (licensed by Perrigo), Dr. Reddy's Labs (licensed by Leiner), Genpharm (1"The Tan Sheet" Jan. 7, 2002, In Brief)...

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts